CVN424

CAS No. 2254706-21-1

CVN424( —— )

Catalog No. M28619 CAS No. 2254706-21-1

CVN424 is a selective and novel GPR6 Inverse agonist effective in models of Parkinson Disease.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 249 In Stock
5MG 236 In Stock
10MG 376 In Stock
25MG 620 In Stock
50MG 877 In Stock
100MG 1144 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CVN424
  • Note
    Research use only, not for human use.
  • Brief Description
    CVN424 is a selective and novel GPR6 Inverse agonist effective in models of Parkinson Disease.
  • Description
    CVN424 is a selective and novel GPR6 Inverse agonist effective in models of Parkinson Disease.(In Vivo): CVN424 is brain-penetrant and shows dose-dependent receptor occupancy that attained brain 50% of receptor occupancy at plasma concentrations of 6.0 and 7.4 ng/ml in mice and rats, respectively.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    GPR
  • Recptor
    5-HT4
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2254706-21-1
  • Formula Weight
    473.52
  • Molecular Formula
    C24H29F2N5O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 62.5 mg/mL (131.99 mM)
  • SMILES
    CC(N(CC1)Cc(nc2N[C@H]3COCC3)c1nc2N(CC1)CCC1Oc(ccc(F)c1)c1F)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.R M Eglen, et al. Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo. Br J Pharmacol. 1995 Aug;115(8):1387-92.
molnova catalog
related products
  • AS 1269574

    AS 1269574 is a potent, orally available GPR119 agonist. AS1269574 has the potential for the research of type 2 diabetes.

  • NCRW0005-F05

    NCRW0005-F05 is a potent agonist of orphan G-protein coupled receptor GPR139 with an IC 50 value of 0.21 μM. NCRW0005-F05 can be used to research diabetes, obesity and Parkinson's disease .

  • BigLEN (mouse)

    GPR171 agonist. ProSAAS-derived neuropeptide. Regulates food intake in mice. Inhibits the release of glutamate onto parvocellular neurons of the paraventricular nucleus in a process dependent upon activation of postsynaptic G proteins.